The upcoming RDD Europe 2025 conference in Estoril, Portugal will mark the 20th anniversary of the … [Read More...] about RDD Europe 2025 preview
RDD Europe 2025 preview
DDL 2024 in review
DDL 2024 drew the largest crowd ever in the 35-year history of the Drug Delivery to the Lung (DDL), … [Read More...] about DDL 2024 in review
DDL 2024 to celebrate 35 years as a leading OINDP conference
The annual Drug Delivery to the Lungs (DDL) conference will mark its 35th anniversary during this … [Read More...] about DDL 2024 to celebrate 35 years as a leading OINDP conference
Latest news
Rein Therapeutics gets 2 new US patents covering its LTI-03 DPI
Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company's lead candidate, LTI-03. Both of the new patents are titled "Dry Powder Formulation of Caveolin-1 … [Read More...] about Rein Therapeutics gets 2 new US patents covering its LTI-03 DPI
Kindeva names Melanie Cerullo as Chief Quality Officer
CDMO Kindeva has announced the appointment of Melanie Cerullo as Chief Quality Officer. Cerullo was most recently Chief Quality and Regulatory Officer at Recipharm's ReciBioPharm business unit and previously served in quality roles at Wave Life Sciences, Ameridose, and Amgen. Since the beginning … [Read More...] about Kindeva names Melanie Cerullo as Chief Quality Officer
Nanopharm announces clinical study to validate SmartTrack platform for demonstration of BE for inhaled drug products
AptarGroup announced that its subsidiary Nanopharm is initiating a clinical study to validate the SmartTrack in-vitro-in-silico modeling platform as an alternative to clinical endpoint studies for determining bioequivalence of inhaled drug products. The study will also collect PK data for validation … [Read More...] about Nanopharm announces clinical study to validate SmartTrack platform for demonstration of BE for inhaled drug products
FDA approves Neurelis’s Valtoco diazepam nasal spray for use in children aged 2-5
Neurelis announced that the FDA has approved the use of Valtoco diazepam nasal spray for the treatment of seizure clusters in children aged 2 years of age and older. The FDA approved Valtoco for use in patients 6 years old and older in January 2020, and the company initiated a Phase 1/2a trial of … [Read More...] about FDA approves Neurelis’s Valtoco diazepam nasal spray for use in children aged 2-5
Aurobindo says FDA issued Form 483 following inspection of North Carolina inhaler manufacturing facility
Aurobindo has reported to the National Stock Exchange of India that the FDA issued a Form 483 on April 11, 2025, one day after the agency completed an inspection of a manufacturing facility in North Carolina, USA. According to the company, the Form 483, which has not yet been published by the FDA, … [Read More...] about Aurobindo says FDA issued Form 483 following inspection of North Carolina inhaler manufacturing facility
Other recent news
- AATec Medical raises €4 million for development of ATL-105 inhaled recombinant AAT
- Orexo announces data from study of intranasal dry powder flu vaccine in rats
- University of Maryland researchers to conduct Phase 2 trial of ENA Respiratory’s INNA-051 dry powder nasal TLR2/6 agonist
- Lonza to develop spray dried formulations of Ethris’s nasal mRNA-based vaccines
- Avalyn announces plans to advance AP02 inhaled nintedanib into Phase 2 trial in IPF patients